Dealing with challenging APIs

March 06, 2025

Remove from favorites

Add to favorites

In a recent interview with Pharmaceutical Technology, Jens Schmidt from Lonza discusses the increasing prevalence of challenging active pharmaceutical ingredients (APIs) in the development pipeline. The demand for innovative pharmaceutical products is rising due to chronic illnesses and an aging global population. This has led to the exploration of more complex APIs, which pose significant development hurdles.

Key drivers for this trend include an improved understanding of biological pathways, the need for high selectivity with minimal side effects, and the development of multi-target drugs to combat pathogen resistance. Formulating these challenging APIs requires advanced techniques to address issues like poor solubility and bioavailability. Schmidt emphasizes the importance of process development, especially for larger molecules, to overcome manufacturing challenges.

For more insights, you can read the full interview on Pharmaceutical Technology's website.